Back to Search
Start Over
Atorvastatin is associated with reduced cisplatin-induced hearing loss
- Source :
- J Clin Invest
- Publication Year :
- 2020
-
Abstract
- BACKGROUND: Cisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in approximately 50% of treated patients. There is a major need for therapies that prevent cisplatin-induced hearing loss. Studies in mice suggest that concurrent use of statins reduces cisplatin-induced hearing loss. METHODS: We examined hearing thresholds from 277 adults treated with cisplatin for head and neck cancer. Pretreatment and posttreatment audiograms were collected within 90 days of initiation and completion of cisplatin therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: Among patients on concurrent atorvastatin, 9.7% experienced a CTCAE grade 2 or higher cisplatin-induced hearing loss compared with 29.4% in nonstatin users (P < 0.0001). A mixed-effect model analysis showed that atorvastatin use was significantly associated with reduced cisplatin-induced hearing loss (P ≤ 0.01). An adjusted odds ratio (OR) analysis indicated that an atorvastatin user is 53% less likely to acquire a cisplatin-induced hearing loss than a nonstatin user (OR = 0.47; 95% CI, 0.30–0.78). Three-year survival rates were not different between atorvastatin users and nonstatin users (P > 0.05). CONCLUSIONS: Our data indicate that atorvastatin use is associated with reduced incidence and severity of cisplatin-induced hearing loss in adults being treated for head and neck cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03225157. FUNDING: Funding was provided by the Division of Intramural Research at the National Institute on Deafness and Other Communication Disorders (1 ZIA DC000079, ZIA DC000090).
- Subjects :
- 0301 basic medicine
Male
medicine.medical_specialty
Hearing loss
Atorvastatin
03 medical and health sciences
0302 clinical medicine
Otology
Internal medicine
medicine
otorhinolaryngologic diseases
Humans
Prospective Studies
Hearing Loss
Aged
Retrospective Studies
business.industry
Incidence (epidemiology)
Incidence
Head and neck cancer
Cancer
Common Terminology Criteria for Adverse Events
General Medicine
Audiogram
Middle Aged
medicine.disease
Ototoxicity
030104 developmental biology
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Female
medicine.symptom
Cisplatin
Clinical Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 15588238
- Volume :
- 131
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- The Journal of clinical investigation
- Accession number :
- edsair.doi.dedup.....262a97e73ad6a24f8e4e517e6ee28b5c